As of 2026-07-31, Miller Convertible Bond Fund held total net Assets of $384955012.24, with Euronet Worldwide, Inc. the largest disclosed holding at $11752619.55000000. The snapshot matters because it shows investors the fund’s asset base, concentration among leading positions and Maturity dates attached to its disclosed Debt holdings.

Key Highlights

  • Euronet Worldwide’s disclosed position carried a $13,000,000 principal amount and matured on 1 October 2030.
  • Citigroup Global Markets Holdings Inc held a $9,500,000 principal amount security maturing on 22 June 2029.
  • Meritage Homes Corp’s position carried a fixed rate of 1.75000000 and matured on 15 May 2028.

Miller Investment Trust’s Miller Convertible Bond Fund held total net assets of $384,955,012.24 as of 31 July 2026.

Portfolio Assets At July 31

Miller Convertible Bond Fund also reported $385,444,580.68 and $489,568.44 in portfolio-level fields associated with the reporting period, alongside the stated net assets of $384,955,012.24. The holdings were marked long, and the reported securities were denominated in USD. Euronet Worldwide, Inc (NASDAQ: EEFT). had a principal amount of $13,000,000, a maturity date of 1 October 2030 and a fixed rate of 0.62500000. Its position value was $11,752,619.55, equal to 3.05% of assets. Its reported value was $9,940,800, or 2.58% of the portfolio. Meritage Homes Corp (NYSE: MTH) had a principal amount of $10,000,000, a 15 May 2028 maturity and a fixed rate of 1.75000000. The position was valued at $9,938,054.91, representing 2.58% of assets. Other disclosed holdings included Blackline Inc, with a principal amount of $8,000,000, a 1 June 2029 maturity and a fixed rate of 1.00000000. Its reported value was $7,477,293.97, or 1.94% of the portfolio. Travere Therapeutics Inc had a principal amount of $100,000, matured on 15 May 2032 and carried a fixed rate of 0.50000000. Its value was $116,829.85, equal to 0.03% of assets. The disclosed maturity dates therefore run from 15 May 2028 for Meritage Homes Corp to 15 May 2032 for Travere Therapeutics Inc.